Research
Hormonal
Semaglutide 1 mg once weekly reduces major adverse renal events (MACEr) in people with Type 2 Diabetes and renal impairment, as investigated in the FLOW study.
If you have Type 2 Diabetes and early-to-moderate kidney disease, discuss the FLOW study findings with your doctor. This once-weekly injection (1 mg) is being tested specifically to protect your kidneys from failing, potentially delaying or preventing the need for dialysis.
StrongSupportsHIGH confidence
The FLOW study is a randomised, double-blind, parallel-group, placebo-controlled trial evaluating the safety and impact of semaglutide 1 mg once weekly in people with renal impairment and T2D on major adverse renal events.
Why this rating
The FLOW study is the first dedicated renal outcomes trial for GLP-1 analogues, powered as a rigorous RCT.
Source
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00917-8
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg once weekly reduces major adverse cardiac events (MACE) in overweight or obese individuals without diabetes, demonstrating cardiovascular benefit independent of glycemic control.Strong
- Previous GLP-1 analogue CVOTs (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) demonstrate a reduction in major adverse cardiac events (MACE) and renal composite outcomes in people with Type 2 Diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →